Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Fecha de publicación: 4 de noviembre de 2026, 9:49

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.